5/12/2025
Last update
5/12/2025
Reviewed By
Overview
SCIENTIFIC SCORE
Questionable
Based on 8 Researches
6.5
USERS' SCORE
Good
Based on 4 Reviews
8.4
Supplement Facts
Serving Size: 3 Soft Gels
Amount Per Serving
%DV
Calories
35
Total Fat
3 g
4%
Saturated Fat
0.5 g
3%
Trans Fat
0 g
†
Cholesterol
15 mg
5%
Vitamin A
30 mcg RAE
3%
Total Omega-3s
750 mg
†
EPA (Eicosapentaenoic Acid)
240 mg
†
DHA (Docosahexaenoic Acid)
360 mg
†
Other Omega-3s
150 mg
†
Top Medical Research Studies
7
We examined how eicosapentaenoic acid (EPA), a key ingredient found in fish oil, impacts chest pain in patients with variant angina. Our study followed 22 individuals with this condition, where we infused acetylcholine, a substance known to cause coronary vasospasm, both before and after a four-month course of EPA treatment (1.8 g/day for 12 patients).
In the group that did not receive EPA, we observed no changes in how their coronary arteries responded to acetylcholine over time. However, for those treated with EPA, the results were quite intriguing. In non-spastic areas, the response shifted from vasoconstriction (narrowing) to vasodilation (widening). This indicates a notable improvement in how these arteries are functioning.
Yet, when it came to spastic sites where vasospasm had occurred, the coronary arteries remained responsive to acetylcholine, and the vasospasm persisted despite the EPA treatment. Thus, while EPA enhanced coronary responsiveness in some areas, it did not eliminate the acetylcholine-induced coronary vasospasms associated with variant angina.
In the group that did not receive EPA, we observed no changes in how their coronary arteries responded to acetylcholine over time. However, for those treated with EPA, the results were quite intriguing. In non-spastic areas, the response shifted from vasoconstriction (narrowing) to vasodilation (widening). This indicates a notable improvement in how these arteries are functioning.
Yet, when it came to spastic sites where vasospasm had occurred, the coronary arteries remained responsive to acetylcholine, and the vasospasm persisted despite the EPA treatment. Thus, while EPA enhanced coronary responsiveness in some areas, it did not eliminate the acetylcholine-induced coronary vasospasms associated with variant angina.
Read More
8
We explored how an eicosapentaenoic acid (EPA)-rich diet influences the generation of thromboxane A2 (TxA2) in patients experiencing first-time angina pectoris. TxA2 plays a crucial role in promoting blood clotting and causing spasms of the blood vessels, both of which are key issues in coronary heart diseases.
Our study compared the effects of an EPA-rich diet with a standard hospital diet on the ability of platelets to generate TxA2 when stimulated by ADP. Among the 12 patients with first angina, those who adhered to the standard hospital diet showed the capacity to produce TxA2 under these conditions. Conversely, those who consumed the EPA-rich diet did not exhibit this same generation of TxA2.
The findings suggest that the fish-based diet rich in EPA may positively affect platelet aggregation. We observed a reduced potential for harmful TxA2 generation in the patients on the EPA-rich diet, indicating a possible lower risk for vascular spasms associated with angina.
In conclusion, while more research is needed to confirm these effects, the initial results reveal that incorporating EPA into the diet might help alleviate some risks associated with chest pain due to its impact on platelet behavior.
Our study compared the effects of an EPA-rich diet with a standard hospital diet on the ability of platelets to generate TxA2 when stimulated by ADP. Among the 12 patients with first angina, those who adhered to the standard hospital diet showed the capacity to produce TxA2 under these conditions. Conversely, those who consumed the EPA-rich diet did not exhibit this same generation of TxA2.
The findings suggest that the fish-based diet rich in EPA may positively affect platelet aggregation. We observed a reduced potential for harmful TxA2 generation in the patients on the EPA-rich diet, indicating a possible lower risk for vascular spasms associated with angina.
In conclusion, while more research is needed to confirm these effects, the initial results reveal that incorporating EPA into the diet might help alleviate some risks associated with chest pain due to its impact on platelet behavior.
Read More
8
We examined the impact of eicosapentaenoic acid—a key component in fish oil—on chest pain among 107 individuals over two years. Ninety-two of these participants had established heart disease or high cholesterol levels, while 15 did not have any history of heart problems.
Through this study, we found that serum triglyceride levels dropped quickly, suggesting a significant benefit for those dealing with high fat in the blood. While cholesterol levels decreased at a slower rate, intriguingly, the levels of good cholesterol (HDL) increased—often associated with better heart health.
Another notable finding was the lengthening of bleeding times and a reduced need for glyceryl trinitrate (GTN) tablets, which are often used to relieve angina attacks. This reduction in angina suggests that eicosapentaenoic acid might help alleviate chest pain by lowering the frequency of angina episodes and affecting platelet behavior, making them less likely to clump together.
However, it is essential to point out that while these changes promote heart health, this study did not compare the fish lipid concentrate with a placebo or an alternative treatment, leaving some of the isolated effects a little unclear. Overall, the trends observed are promising for heart disease management but should be interpreted with caution.
Through this study, we found that serum triglyceride levels dropped quickly, suggesting a significant benefit for those dealing with high fat in the blood. While cholesterol levels decreased at a slower rate, intriguingly, the levels of good cholesterol (HDL) increased—often associated with better heart health.
Another notable finding was the lengthening of bleeding times and a reduced need for glyceryl trinitrate (GTN) tablets, which are often used to relieve angina attacks. This reduction in angina suggests that eicosapentaenoic acid might help alleviate chest pain by lowering the frequency of angina episodes and affecting platelet behavior, making them less likely to clump together.
However, it is essential to point out that while these changes promote heart health, this study did not compare the fish lipid concentrate with a placebo or an alternative treatment, leaving some of the isolated effects a little unclear. Overall, the trends observed are promising for heart disease management but should be interpreted with caution.
Read More
Most Useful Reviews
7.5
Reduced joint pain
1 people found this helpful
No Cod Liver Oil taste! I've been taking this for a while now and I keep waiting for that awful flavour to start reappearing, but it doesn't! It's fantastic, plus the health benefits - I have noticed a reduction of joint pain with the CLO.
Read More
9
Minimal arthritis pain
Great product! This is an amazing item. I didn't start taking it for arthritis, but within two weeks my arthritis pain became only occasionally minimal. I have recommended this product to several people.
Read More
9
Removed my pain
Great for my autoimmune condition. It effectively removes my pain. I have tried many things.
Read More
Medical Researches
SCIENTIFIC SCORE
Questionable
Based on 8 Researches
6.5
- All Researches
8
Eicosapentaenoic acid’s effects inconclusive
We conducted a randomized, double-blind, placebo-controlled trial to assess how eicosapentaenoic acid, found in fish oil, might impact chest pain in patients experiencing suspected acute myocardial infarction (AMI). Over one year, we compared outcomes among groups taking fish oil, mustard oil, and a placebo, all starting treatment roughly 18 hours after symptoms appeared.
Our findings highlighted that both fish oil and mustard oil groups experienced fewer overall cardiac events compared to the placebo group. However, while we did observe reductions in nonfatal infarctions and total cardiac deaths within the fish oil group, there was no similar reduction in chest pain or direct measures of angina specifically linked to these treatments.
Interestingly, the study indicated that levels of cardiac arrhythmias and left ventricular enlargement were also reduced in those taking fish oil and mustard oil compared to those on a placebo. While we saw some improvements in overall cardiac health, the direct effects on chest pain from taking eicosapentaenoic acid were not conclusively established in this trial.
Ultimately, although fish oil shows promise in improving various heart-related outcomes, the specific impact on chest pain wasn't distinctly proven through our study results. Further extensive research will be essential to draw firmer conclusions.
Our findings highlighted that both fish oil and mustard oil groups experienced fewer overall cardiac events compared to the placebo group. However, while we did observe reductions in nonfatal infarctions and total cardiac deaths within the fish oil group, there was no similar reduction in chest pain or direct measures of angina specifically linked to these treatments.
Interestingly, the study indicated that levels of cardiac arrhythmias and left ventricular enlargement were also reduced in those taking fish oil and mustard oil compared to those on a placebo. While we saw some improvements in overall cardiac health, the direct effects on chest pain from taking eicosapentaenoic acid were not conclusively established in this trial.
Ultimately, although fish oil shows promise in improving various heart-related outcomes, the specific impact on chest pain wasn't distinctly proven through our study results. Further extensive research will be essential to draw firmer conclusions.
Read More
8
We explored how an eicosapentaenoic acid (EPA)-rich diet influences the generation of thromboxane A2 (TxA2) in patients experiencing first-time angina pectoris. TxA2 plays a crucial role in promoting blood clotting and causing spasms of the blood vessels, both of which are key issues in coronary heart diseases.
Our study compared the effects of an EPA-rich diet with a standard hospital diet on the ability of platelets to generate TxA2 when stimulated by ADP. Among the 12 patients with first angina, those who adhered to the standard hospital diet showed the capacity to produce TxA2 under these conditions. Conversely, those who consumed the EPA-rich diet did not exhibit this same generation of TxA2.
The findings suggest that the fish-based diet rich in EPA may positively affect platelet aggregation. We observed a reduced potential for harmful TxA2 generation in the patients on the EPA-rich diet, indicating a possible lower risk for vascular spasms associated with angina.
In conclusion, while more research is needed to confirm these effects, the initial results reveal that incorporating EPA into the diet might help alleviate some risks associated with chest pain due to its impact on platelet behavior.
Our study compared the effects of an EPA-rich diet with a standard hospital diet on the ability of platelets to generate TxA2 when stimulated by ADP. Among the 12 patients with first angina, those who adhered to the standard hospital diet showed the capacity to produce TxA2 under these conditions. Conversely, those who consumed the EPA-rich diet did not exhibit this same generation of TxA2.
The findings suggest that the fish-based diet rich in EPA may positively affect platelet aggregation. We observed a reduced potential for harmful TxA2 generation in the patients on the EPA-rich diet, indicating a possible lower risk for vascular spasms associated with angina.
In conclusion, while more research is needed to confirm these effects, the initial results reveal that incorporating EPA into the diet might help alleviate some risks associated with chest pain due to its impact on platelet behavior.
Read More
8
We examined the impact of eicosapentaenoic acid—a key component in fish oil—on chest pain among 107 individuals over two years. Ninety-two of these participants had established heart disease or high cholesterol levels, while 15 did not have any history of heart problems.
Through this study, we found that serum triglyceride levels dropped quickly, suggesting a significant benefit for those dealing with high fat in the blood. While cholesterol levels decreased at a slower rate, intriguingly, the levels of good cholesterol (HDL) increased—often associated with better heart health.
Another notable finding was the lengthening of bleeding times and a reduced need for glyceryl trinitrate (GTN) tablets, which are often used to relieve angina attacks. This reduction in angina suggests that eicosapentaenoic acid might help alleviate chest pain by lowering the frequency of angina episodes and affecting platelet behavior, making them less likely to clump together.
However, it is essential to point out that while these changes promote heart health, this study did not compare the fish lipid concentrate with a placebo or an alternative treatment, leaving some of the isolated effects a little unclear. Overall, the trends observed are promising for heart disease management but should be interpreted with caution.
Through this study, we found that serum triglyceride levels dropped quickly, suggesting a significant benefit for those dealing with high fat in the blood. While cholesterol levels decreased at a slower rate, intriguingly, the levels of good cholesterol (HDL) increased—often associated with better heart health.
Another notable finding was the lengthening of bleeding times and a reduced need for glyceryl trinitrate (GTN) tablets, which are often used to relieve angina attacks. This reduction in angina suggests that eicosapentaenoic acid might help alleviate chest pain by lowering the frequency of angina episodes and affecting platelet behavior, making them less likely to clump together.
However, it is essential to point out that while these changes promote heart health, this study did not compare the fish lipid concentrate with a placebo or an alternative treatment, leaving some of the isolated effects a little unclear. Overall, the trends observed are promising for heart disease management but should be interpreted with caution.
Read More
7
We explored how eicosapentaenoic acid (EPA), a type of omega-3 fatty acid, might play a role in managing chest pain, particularly for those suffering from coronary spastic angina (CSA). In our study, we looked at 406 patients who underwent an ergonovine tolerance test during coronary angiography to diagnose CSA.
The patients were divided into two age groups: young individuals (65 years or younger) and elderly individuals (older than 66). We found that for younger patients who tested positive for CSA, their serum levels of EPA were significantly higher compared to those without CSA. Specifically, the levels of EPA were 64.3 μg/mL in the CSA-positive group versus 49.4 μg/mL in the CSA-negative group, and this difference was statistically significant. Furthermore, docosahexaenoic acid (DHA) levels also followed a similar pattern.
However, the same pattern did not hold for the elderly group, where the levels of these fatty acids did not show a clear relationship with CSA. Through our multivariate analysis, it became clear that higher levels of EPA and DHA were independently associated with CSA in younger patients, suggesting that these fatty acids may be influential in the pathophysiology of chest pain linked to CSA for this demographic.
Overall, while we demonstrated some intriguing links between EPA levels and chest pain in younger individuals, we found that these associations do not translate similarly for older adults.
The patients were divided into two age groups: young individuals (65 years or younger) and elderly individuals (older than 66). We found that for younger patients who tested positive for CSA, their serum levels of EPA were significantly higher compared to those without CSA. Specifically, the levels of EPA were 64.3 μg/mL in the CSA-positive group versus 49.4 μg/mL in the CSA-negative group, and this difference was statistically significant. Furthermore, docosahexaenoic acid (DHA) levels also followed a similar pattern.
However, the same pattern did not hold for the elderly group, where the levels of these fatty acids did not show a clear relationship with CSA. Through our multivariate analysis, it became clear that higher levels of EPA and DHA were independently associated with CSA in younger patients, suggesting that these fatty acids may be influential in the pathophysiology of chest pain linked to CSA for this demographic.
Overall, while we demonstrated some intriguing links between EPA levels and chest pain in younger individuals, we found that these associations do not translate similarly for older adults.
Read More
7
We investigated whether adding eicosapentaenoic acid (EPA) to high-dose pitavastatin could enhance coronary plaque regression and help manage chest pain in patients with coronary heart disease (CHD). In a randomized controlled trial, 193 CHD patients who received percutaneous coronary intervention were divided into two groups: one received pitavastatin alone, while the other received both pitavastatin and EPA.
Over a period of 6 to 8 months, we observed that the combination of EPA and pitavastatin notably reduced coronary plaque volume compared to pitavastatin alone. This reduction was particularly significant for patients with stable angina pectoris (SAP), suggesting that EPA may have a more beneficial effect on chest pain in these patients.
However, despite the promising results for plaque reduction, the study did not report a direct decrease in the incidence of chest pain as a significant outcome measure. Overall, while EPA treatment appears to support coronary health and may be more effective for certain patients, the specific impact on chest pain requires further exploration.
Over a period of 6 to 8 months, we observed that the combination of EPA and pitavastatin notably reduced coronary plaque volume compared to pitavastatin alone. This reduction was particularly significant for patients with stable angina pectoris (SAP), suggesting that EPA may have a more beneficial effect on chest pain in these patients.
However, despite the promising results for plaque reduction, the study did not report a direct decrease in the incidence of chest pain as a significant outcome measure. Overall, while EPA treatment appears to support coronary health and may be more effective for certain patients, the specific impact on chest pain requires further exploration.
Read More
User Reviews
USERS' SCORE
Good
Based on 4 Reviews
8.4
- All Reviews
- Positive Reviews
- Negative Reviews
7.5
Reduced joint pain
1 people found this helpful
No Cod Liver Oil taste! I've been taking this for a while now and I keep waiting for that awful flavour to start reappearing, but it doesn't! It's fantastic, plus the health benefits - I have noticed a reduction of joint pain with the CLO.
Read More
9
Minimal arthritis pain
Great product! This is an amazing item. I didn't start taking it for arthritis, but within two weeks my arthritis pain became only occasionally minimal. I have recommended this product to several people.
Read More
9
Removed my pain
Great for my autoimmune condition. It effectively removes my pain. I have tried many things.
Read More
7.5
Relieved pain
Firstly, the connection was quick and the yield was excellent, improving flexibility and relieving pain.
Read More
Frequently Asked Questions
9
Minimal arthritis pain
Great product! This is an amazing item. I didn't start taking it for arthritis, but within two weeks my arthritis pain became only occasionally minimal. I have recommended this product to several people.
9
Removed my pain
Great for my autoimmune condition. It effectively removes my pain. I have tried many things.
7.5
Reduced joint pain
1 people found this helpful
No Cod Liver Oil taste! I've been taking this for a while now and I keep waiting for that awful flavour to start reappearing, but it doesn't! It's fantastic, plus the health benefits - I have noticed a reduction of joint pain with the CLO.
7.5
Relieved pain
Firstly, the connection was quick and the yield was excellent, improving flexibility and relieving pain.
7
We explored how eicosapentaenoic acid (EPA), a type of omega-3 fatty acid, might play a role in managing chest pain, particularly for those suffering from coronary spastic angina (CSA). In our study, we looked at 406 patients who underwent an ergonovine tolerance test during coronary angiography to diagnose CSA.
The patients were divided into two age groups: young individuals (65 years or younger) and elderly individuals (older than 66). We found that for younger patients who tested positive for CSA, their serum levels of EPA were significantly higher compared to those without CSA. Specifically, the levels of EPA were 64.3 μg/mL in the CSA-positive group versus 49.4 μg/mL in the CSA-negative group, and this difference was statistically significant. Furthermore, docosahexaenoic acid (DHA) levels also followed a similar pattern.
However, the same pattern did not hold for the elderly group, where the levels of these fatty acids did not show a clear relationship with CSA. Through our multivariate analysis, it became clear that higher levels of EPA and DHA were independently associated with CSA in younger patients, suggesting that these fatty acids may be influential in the pathophysiology of chest pain linked to CSA for this demographic.
Overall, while we demonstrated some intriguing links between EPA levels and chest pain in younger individuals, we found that these associations do not translate similarly for older adults.
The patients were divided into two age groups: young individuals (65 years or younger) and elderly individuals (older than 66). We found that for younger patients who tested positive for CSA, their serum levels of EPA were significantly higher compared to those without CSA. Specifically, the levels of EPA were 64.3 μg/mL in the CSA-positive group versus 49.4 μg/mL in the CSA-negative group, and this difference was statistically significant. Furthermore, docosahexaenoic acid (DHA) levels also followed a similar pattern.
However, the same pattern did not hold for the elderly group, where the levels of these fatty acids did not show a clear relationship with CSA. Through our multivariate analysis, it became clear that higher levels of EPA and DHA were independently associated with CSA in younger patients, suggesting that these fatty acids may be influential in the pathophysiology of chest pain linked to CSA for this demographic.
Overall, while we demonstrated some intriguing links between EPA levels and chest pain in younger individuals, we found that these associations do not translate similarly for older adults.
7
We investigated whether adding eicosapentaenoic acid (EPA) to high-dose pitavastatin could enhance coronary plaque regression and help manage chest pain in patients with coronary heart disease (CHD). In a randomized controlled trial, 193 CHD patients who received percutaneous coronary intervention were divided into two groups: one received pitavastatin alone, while the other received both pitavastatin and EPA.
Over a period of 6 to 8 months, we observed that the combination of EPA and pitavastatin notably reduced coronary plaque volume compared to pitavastatin alone. This reduction was particularly significant for patients with stable angina pectoris (SAP), suggesting that EPA may have a more beneficial effect on chest pain in these patients.
However, despite the promising results for plaque reduction, the study did not report a direct decrease in the incidence of chest pain as a significant outcome measure. Overall, while EPA treatment appears to support coronary health and may be more effective for certain patients, the specific impact on chest pain requires further exploration.
Over a period of 6 to 8 months, we observed that the combination of EPA and pitavastatin notably reduced coronary plaque volume compared to pitavastatin alone. This reduction was particularly significant for patients with stable angina pectoris (SAP), suggesting that EPA may have a more beneficial effect on chest pain in these patients.
However, despite the promising results for plaque reduction, the study did not report a direct decrease in the incidence of chest pain as a significant outcome measure. Overall, while EPA treatment appears to support coronary health and may be more effective for certain patients, the specific impact on chest pain requires further exploration.
8
Eicosapentaenoic acid’s effects inconclusive
We conducted a randomized, double-blind, placebo-controlled trial to assess how eicosapentaenoic acid, found in fish oil, might impact chest pain in patients experiencing suspected acute myocardial infarction (AMI). Over one year, we compared outcomes among groups taking fish oil, mustard oil, and a placebo, all starting treatment roughly 18 hours after symptoms appeared.
Our findings highlighted that both fish oil and mustard oil groups experienced fewer overall cardiac events compared to the placebo group. However, while we did observe reductions in nonfatal infarctions and total cardiac deaths within the fish oil group, there was no similar reduction in chest pain or direct measures of angina specifically linked to these treatments.
Interestingly, the study indicated that levels of cardiac arrhythmias and left ventricular enlargement were also reduced in those taking fish oil and mustard oil compared to those on a placebo. While we saw some improvements in overall cardiac health, the direct effects on chest pain from taking eicosapentaenoic acid were not conclusively established in this trial.
Ultimately, although fish oil shows promise in improving various heart-related outcomes, the specific impact on chest pain wasn't distinctly proven through our study results. Further extensive research will be essential to draw firmer conclusions.
Our findings highlighted that both fish oil and mustard oil groups experienced fewer overall cardiac events compared to the placebo group. However, while we did observe reductions in nonfatal infarctions and total cardiac deaths within the fish oil group, there was no similar reduction in chest pain or direct measures of angina specifically linked to these treatments.
Interestingly, the study indicated that levels of cardiac arrhythmias and left ventricular enlargement were also reduced in those taking fish oil and mustard oil compared to those on a placebo. While we saw some improvements in overall cardiac health, the direct effects on chest pain from taking eicosapentaenoic acid were not conclusively established in this trial.
Ultimately, although fish oil shows promise in improving various heart-related outcomes, the specific impact on chest pain wasn't distinctly proven through our study results. Further extensive research will be essential to draw firmer conclusions.
4
We examined the effects of fish oil, particularly focusing on eicosapentaenoic acid, in patients with stable angina pectoris. In the study, participants first received a supplement of n-6 polyunsaturated fatty acids for four weeks. After this initial phase, they were randomly assigned to continue with the same oil or switch to fish oil, which included n-3 polyunsaturated fatty acids, for an additional 12 weeks.
Blood samples were collected before and after the 16 weeks of supplementation to look at changes in lipids, coagulation, and fibrinolysis. Although we found significant reductions in triglycerides and very low-density lipoproteins, we also saw an unexpected rise in total cholesterol levels from 5.9 to 6.7 mmol/L after taking fish oil.
It’s important to note that we observed a decrease in fibrinolytic activity at rest following the fish oil supplementation. Other measurements showed no statistically significant changes, which leads us to conclude that there isn't strong evidence to suggest that eicosapentaenoic acid directly alleviates chest pain in these patients. Therefore, we recommend caution with the uncontrolled use of fish oil supplements for patients experiencing stable angina pectoris.
Blood samples were collected before and after the 16 weeks of supplementation to look at changes in lipids, coagulation, and fibrinolysis. Although we found significant reductions in triglycerides and very low-density lipoproteins, we also saw an unexpected rise in total cholesterol levels from 5.9 to 6.7 mmol/L after taking fish oil.
It’s important to note that we observed a decrease in fibrinolytic activity at rest following the fish oil supplementation. Other measurements showed no statistically significant changes, which leads us to conclude that there isn't strong evidence to suggest that eicosapentaenoic acid directly alleviates chest pain in these patients. Therefore, we recommend caution with the uncontrolled use of fish oil supplements for patients experiencing stable angina pectoris.
References
- Tawara K, Akioka H, Sato H, Sato T, Takahashi M, et al. Role of polyunsaturated fatty acids in Japanese patients with coronary spastic angina. J Cardiol. 2023;82:455. 10.1016/j.jjcc.2023.07.001
- Watanabe T, Ando K, Daidoji H, Otaki Y, Sugawara S, et al. A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins. J Cardiol. 2017;70:537. 10.1016/j.jjcc.2017.07.007
- Singh RB, Niaz MA, Sharma JP, Kumar R, Rastogi V, et al. Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: the Indian experiment of infarct survival--4. Cardiovasc Drugs Ther. 1997;11:485.
- Yamamoto H, Yoshimura H, Noma M, Suzuki S, Kai H, et al. Improvement of coronary vasomotion with eicosapentaenoic acid does not inhibit acetylcholine-induced coronary vasospasm in patients with variant angina. Jpn Circ J. 1995;59:608.
- Zykova VP, Perova NV, Kalinkina OM. [Study of in vitro thromboxane A2 generation by platelets of patients with first-time appearing angina pectoris under the effect of fish diet]. Kardiologiia. 1990;30:24.
- Schmidt EB, Kristensen SD, Dyerberg J. The effect of fish oil on lipids, coagulation and fibrinolysis in patients with angina pectoris. Artery. 1988;15:316.
- Kondo T, Ogawa K, Satake T, Kitazawa M, Taki K, et al. Plasma-free eicosapentaenoic acid/arachidonic acid ratio: a possible new coronary risk factor. Clin Cardiol. 1986;9:413.
- Saynor R, Verel D, Gillott T. The long-term effect of dietary supplementation with fish lipid concentrate on serum lipids, bleeding time, platelets and angina. Atherosclerosis. 1984;50:3.
